Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K, Rauchhaus P, Littleford R, Cheung SYA, Cullberg M, de Bruin EC, Koulai L, Lindemann JPO, Pass M, Rugman P, Schiavon G, Deb R, Finlay P, Foxley A, Gee JMW.
Robertson JFR, et al. Among authors: rauchhaus p.
Clin Cancer Res. 2020 Apr 1;26(7):1574-1585. doi: 10.1158/1078-0432.CCR-19-3053. Epub 2019 Dec 13.
Clin Cancer Res. 2020.
PMID: 31836609
Free article.
Clinical Trial.